

(4) Arcamone, F., Franceschi, G., Orezzi, P., Cassinelli, G., Barbieri, W., and Mondelli, R., *J. Am. Chem. Soc.*, **86**, 5334, 5335(1964).

Life Sciences Research
Stanford Research Institute
Menlo Park, CA 94025

GEORGE L. TONG
PETER LIM
LEON GOODMAN

Received August 11, 1967.
Accepted for publication October 4, 1967.

This work was carried out under the auspices of the Cancer Chemotherapy National Service Center, National Cancer Institute, National Institutes of Health, U. S. Public Health Service, Bethesda, Md., under contract PH-43-64-500.

Errata

In the article titled "New Compounds: Synthesis of Some Sulfazopyridines for Pharmacological Study" (1), the first author's name, page 1358, should read:

Hassan Y. Aboul-Enein

(1) Aboul-Enein, H. Y., Khalifa, M., and Abou-Zeid, Y. M., *J. Pharm. Sci.*, **56**, 1358(1967).

In the article titled "Irreversible Enzyme Inhibitors LXXXII. Candidate Active-Site-Directed Irreversible Inhibitors of Dihydrofolic Reductase VII. Derivatives of 2,4-Diaminopyrimidine I" (1), the following correction should be made:

In Table I on page 568 under "% Inactivation" the number opposite compound XII should read "0f."

(1) Baker, B. R., Jackson, G. D. F., and Meyer, R. B., Jr., *J. Pharm. Sci.*, **56**, 566(1967).

In the Book Review titled "Nonionic Surfactants" (1), the following correction should be made on page 664:

Reviewed by James Swarbrick
School of Pharmacy
University of Connecticut
Storrs, Conn.

(1) Swarbrick, J., *J. Pharm. Sci.*, **56**, 663(1967).

In the article titled "Acetylation of Acetaminophen in Tablet Formulations Containing Aspirin" (1), the following correction should be made in Table II, page 1120:

Under "DAPAP, mg./Tab.," between 4.13 and 36, insert "DAPAP, mcg./Tab."

(1) Koshy, K. T., Troup, A. E., Duvall, R. N., Conwell, R. C., and Shankle, L. L., *J. Pharm. Sci.*, **56**, 1117(1967).

In the article titled "Diffusion of Drugs Across the Isolated Mesentery" (1), *References 8 and 11*, page 469, should read:

(8) Engle, D., and Kerekes, A., *Klin. Wochschr.*, **5**, 1709(1926); through *Chem. Abstr.*, **21**, 133(1927).

(11) Brodie, B. B., Burns, J. J., Mark, L. C., Lief, P. A., Bernstein, E., and Papper, E. M., *J. Pharmacol. Exptl. Therap.*, **109**, 26(1953).

(1) Shenouda, L. S., and Mattocks, A. M., *J. Pharm. Sci.*, **56**, 464(1967).

In the article titled "Radiopharmaceuticals" (1), the following corrections should be made:

1. On page 1, column 1, the first footnote paragraph should read:

Received from the Department of Pharmaceutical Chemistry, School of Pharmacy, University of Southern California, Los Angeles, CA 90007, and the *Radioisotope Research Laboratory, Veterans Administration Center and Department of Radiology, School of Medicine, University of California at Los Angeles, Los Angeles, CA 90024

2. On page 5, *Footnotes 1 and 2* should read:

¹ Marketed as Hippuran-131 by Abbott Laboratories, North Chicago, Ill., as Hipputope by E. R. Squibb & Sons, New York, N. Y., and as Hippuran I 131 by Nuclear Consultants, Chicago, Ill.

² Marketed as Ethiodol-131 by Abbott Laboratories, North Chicago, Ill.

3. On page 14, column 2, line 32, ^{99m}Tc should read ^{99m}Tc.

(1) Wolf, W., and Tubis, M., *J. Pharm. Sci.*, **56**, 1(1967).

In the article titled "Pemoline and Magnesium Hydroxide Versus Pemoline: Enhancement of Learning and Memory of a Conditioned Avoidance Response in Rats" (1), the following corrections should be made:

1. On page 290, *Footnote 1* should read:

¹ Tradenamed as Cylert by Abbott Laboratories, North Chicago, Ill. Abbott-30400: an equimolar combination of 2-imino-5-phenyl-4-oxazolidinone (Abbott-13397) and magnesium hydroxide.

2. On page 291, *Footnote b* in Table II should read:

^b Mean jump-out time significantly different from controls *p* 0.05 (10).

(1) Plotnikoff, N., and Meekma, P., Jr., *J. Pharm. Sci.*, **56**, 290(1967).